The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access

Jonne Terstappen; Sarah F. Hak; Anant Bhan; Debby Bogaert; Louis J. Bont; Ursula J. Buchholz; Andrew D. Clark; Cheryl Cohen; Ron Dagan; Daniel R. Feikin; Barney S. Graham; Anuradha Gupta; Pradeep Haldar; Rose Jalang'o; Ruth A. Karron; Leyla Kragten; You Li; Yvette N. Löwensteyn; Patrick K. Munywoki; Rosemary Njogu; Ab Osterhaus; Andrew J. Pollard; Luiza Reali Nazario; Charles Sande; Ashish R. Satav; Padmini Srikantiah; Renato T. Stein; Naveen Thacker; Rachael Thomas; Marta Tufet Bayona; Natalie I. Mazur

doi:10.1016/S1473-3099(24)00455-9

The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access

Jonne Terstappen, Sarah F. Hak, Anant Bhan, Debby Bogaert, Louis J. Bont, Ursula J. Buchholz, Andrew D. Clark, Cheryl Cohen, Ron Dagan, Daniel R. Feikin, Barney S. Graham, Anuradha Gupta, Pradeep Haldar, Rose Jalang'o, Ruth A. Karron, Leyla Kragten, You Li, Yvette N. Löwensteyn, Patrick K. Munywoki, Rosemary NjoguAb Osterhaus, Andrew J. Pollard, Luiza Reali Nazario, Charles Sande, Ashish R. Satav, Padmini Srikantiah, Renato T. Stein, Naveen Thacker, Rachael Thomas, Marta Tufet Bayona, Natalie I. Mazur

The Shraga Segal Department of Microbiology and Immunology

Ben-Gurion University of the Negev

Research output: Contribution to journal › Review article › peer-review

Abstract

Respiratory syncytial virus (RSV) is the second most common pathogen causing infant mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age ≥60 years) similar to influenza. A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved to protect infants, while an mRNA and two protein-based vaccines are approved for older adults. First-year experience protecting infants with nirsevimab in high-income countries shows a major public health benefit. It is expected that the RSV vaccine landscape will continue to develop in the coming years to protect all people globally. The vaccine and mAb landscape remain active with 30 candidates in clinical development using four approaches: protein-based, live-attenuated and chimeric vector, mRNA, and mAbs. Candidates in late-phase trials aim to protect young infants using mAbs, older infants and toddlers with live-attenuated vaccines, and children and adults using protein-based and mRNA vaccines. This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, we outline urgent next steps to minimise the vaccine delay.

Original language	American English
Pages (from-to)	e747-e761
Journal	The Lancet Infectious Diseases
Volume	24
Issue number	12
DOIs	https://doi.org/10.1016/S1473-3099(24)00455-9
State	Published - 1 Dec 2024

All Science Journal Classification (ASJC) codes

Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1473-3099(24)00455-9

Cite this

Terstappen, J., Hak, S. F., Bhan, A., Bogaert, D., Bont, L. J., Buchholz, U. J., Clark, A. D., Cohen, C., Dagan, R., Feikin, D. R., Graham, B. S., Gupta, A., Haldar, P., Jalang'o, R., Karron, R. A., Kragten, L., Li, Y., Löwensteyn, Y. N., Munywoki, P. K., ... Mazur, N. I. (2024). The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access. The Lancet Infectious Diseases, 24(12), e747-e761. https://doi.org/10.1016/S1473-3099(24)00455-9

@article{48bfb1393e184cbbbf155ae48f982641,

title = "The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access",

abstract = "Respiratory syncytial virus (RSV) is the second most common pathogen causing infant mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age ≥60 years) similar to influenza. A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved to protect infants, while an mRNA and two protein-based vaccines are approved for older adults. First-year experience protecting infants with nirsevimab in high-income countries shows a major public health benefit. It is expected that the RSV vaccine landscape will continue to develop in the coming years to protect all people globally. The vaccine and mAb landscape remain active with 30 candidates in clinical development using four approaches: protein-based, live-attenuated and chimeric vector, mRNA, and mAbs. Candidates in late-phase trials aim to protect young infants using mAbs, older infants and toddlers with live-attenuated vaccines, and children and adults using protein-based and mRNA vaccines. This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, we outline urgent next steps to minimise the vaccine delay.",

author = "Jonne Terstappen and Hak, {Sarah F.} and Anant Bhan and Debby Bogaert and Bont, {Louis J.} and Buchholz, {Ursula J.} and Clark, {Andrew D.} and Cheryl Cohen and Ron Dagan and Feikin, {Daniel R.} and Graham, {Barney S.} and Anuradha Gupta and Pradeep Haldar and Rose Jalang'o and Karron, {Ruth A.} and Leyla Kragten and You Li and L{\"o}wensteyn, {Yvette N.} and Munywoki, {Patrick K.} and Rosemary Njogu and Ab Osterhaus and Pollard, {Andrew J.} and Nazario, {Luiza Reali} and Charles Sande and Satav, {Ashish R.} and Padmini Srikantiah and Stein, {Renato T.} and Naveen Thacker and Rachael Thomas and Bayona, {Marta Tufet} and Mazur, {Natalie I.}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = dec,

day = "1",

doi = "10.1016/S1473-3099(24)00455-9",

language = "American English",

volume = "24",

pages = "e747--e761",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier Ltd.",

number = "12",

}

Terstappen, J, Hak, SF, Bhan, A, Bogaert, D, Bont, LJ, Buchholz, UJ, Clark, AD, Cohen, C, Dagan, R, Feikin, DR, Graham, BS, Gupta, A, Haldar, P, Jalang'o, R, Karron, RA, Kragten, L, Li, Y, Löwensteyn, YN, Munywoki, PK, Njogu, R, Osterhaus, A, Pollard, AJ, Nazario, LR, Sande, C, Satav, AR, Srikantiah, P, Stein, RT, Thacker, N, Thomas, R, Bayona, MT & Mazur, NI 2024, 'The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access', The Lancet Infectious Diseases, vol. 24, no. 12, pp. e747-e761. https://doi.org/10.1016/S1473-3099(24)00455-9

TY - JOUR

T1 - The respiratory syncytial virus vaccine and monoclonal antibody landscape

T2 - the road to global access

AU - Terstappen, Jonne

AU - Hak, Sarah F.

AU - Bhan, Anant

AU - Bogaert, Debby

AU - Bont, Louis J.

AU - Buchholz, Ursula J.

AU - Clark, Andrew D.

AU - Cohen, Cheryl

AU - Dagan, Ron

AU - Feikin, Daniel R.

AU - Graham, Barney S.

AU - Gupta, Anuradha

AU - Haldar, Pradeep

AU - Jalang'o, Rose

AU - Karron, Ruth A.

AU - Kragten, Leyla

AU - Li, You

AU - Löwensteyn, Yvette N.

AU - Munywoki, Patrick K.

AU - Njogu, Rosemary

AU - Osterhaus, Ab

AU - Pollard, Andrew J.

AU - Nazario, Luiza Reali

AU - Sande, Charles

AU - Satav, Ashish R.

AU - Srikantiah, Padmini

AU - Stein, Renato T.

AU - Thacker, Naveen

AU - Thomas, Rachael

AU - Bayona, Marta Tufet

AU - Mazur, Natalie I.

PY - 2024/12/1

Y1 - 2024/12/1

N2 - Respiratory syncytial virus (RSV) is the second most common pathogen causing infant mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age ≥60 years) similar to influenza. A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved to protect infants, while an mRNA and two protein-based vaccines are approved for older adults. First-year experience protecting infants with nirsevimab in high-income countries shows a major public health benefit. It is expected that the RSV vaccine landscape will continue to develop in the coming years to protect all people globally. The vaccine and mAb landscape remain active with 30 candidates in clinical development using four approaches: protein-based, live-attenuated and chimeric vector, mRNA, and mAbs. Candidates in late-phase trials aim to protect young infants using mAbs, older infants and toddlers with live-attenuated vaccines, and children and adults using protein-based and mRNA vaccines. This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, we outline urgent next steps to minimise the vaccine delay.

AB - Respiratory syncytial virus (RSV) is the second most common pathogen causing infant mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age ≥60 years) similar to influenza. A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved to protect infants, while an mRNA and two protein-based vaccines are approved for older adults. First-year experience protecting infants with nirsevimab in high-income countries shows a major public health benefit. It is expected that the RSV vaccine landscape will continue to develop in the coming years to protect all people globally. The vaccine and mAb landscape remain active with 30 candidates in clinical development using four approaches: protein-based, live-attenuated and chimeric vector, mRNA, and mAbs. Candidates in late-phase trials aim to protect young infants using mAbs, older infants and toddlers with live-attenuated vaccines, and children and adults using protein-based and mRNA vaccines. This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, we outline urgent next steps to minimise the vaccine delay.

UR - http://www.scopus.com/inward/record.url?scp=85204808726&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(24)00455-9

DO - 10.1016/S1473-3099(24)00455-9

M3 - Review article

C2 - 39326422

SN - 1473-3099

VL - 24

SP - e747-e761

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 12

ER -

The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this